Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-02-22
2005-02-22
Spector, Lorraine (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069100, C435S069900, C435S320100, C435S356000, C435S358000, C435S361000, C435S252300, C435S254110, C435S254200, C530S412000, C536S023100, C536S023500
Reexamination Certificate
active
06858409
ABSTRACT:
Compounds are disclosed having the general formula R1—X—R2, wherein R1and R2are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1and R2may be the same or different. Preferred R1and R2groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.
REFERENCES:
patent: 4935343 (1990-06-01), Allison et al.
patent: 4956381 (1990-09-01), Bollinger et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5041554 (1991-08-01), Parker et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5453490 (1995-09-01), Hageman et al.
patent: 5455330 (1995-10-01), Haskill et al.
patent: 5508262 (1996-04-01), Norman, Jr.
patent: 5747072 (1998-05-01), Davidson et al.
patent: 5747444 (1998-05-01), Haskill et al.
patent: 5770401 (1998-06-01), Mullarkey
patent: 0343684 (1989-11-01), None
patent: 0 398 817 (1990-11-01), None
patent: WO 8810299 (1988-12-01), None
patent: WO 8901946 (1989-03-01), None
patent: WO 8911540 (1989-11-01), None
patent: WO 9100742 (1991-01-01), None
patent: WO 9108285 (1991-06-01), None
patent: WO 9117184 (1991-11-01), None
patent: WO 9117249 (1991-11-01), None
patent: WO 9212724 (1992-08-01), None
patent: WO 9216221 (1992-10-01), None
patent: WO 9302692 (1993-02-01), None
patent: WO 9307863 (1993-04-01), None
patent: WO 9308304 (1993-04-01), None
patent: WO 9308819 (1993-05-01), None
patent: WO 9308820 (1993-05-01), None
patent: WO 9318783 (1993-09-01), None
patent: WO 9321946 (1993-11-01), None
patent: WO 9324134 (1993-12-01), None
patent: WO 9406457 (1994-03-01), None
patent: WO 9420517 (1994-09-01), None
patent: WO 9421235 (1994-09-01), None
patent: WO 9421275 (1994-09-01), None
patent: WO 9510298 (1995-04-01), None
patent: WO 9516353 (1995-06-01), None
patent: WO 9516706 (1995-06-01), None
patent: WO 9609323 (1996-03-01), None
Hannum et al., Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor, Nature, 343:336-340, Jan. 1990.*
Eisenberg et al., Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist, Nature, 343:341-346, Jan. 1990.*
Watson et al., Molecular Biology of the Gene, Fourth Ed., Benjamin/Cummings Publishing:Menlo Park, CA, p. 313, 1987.*
Liao et al., Characterization of a human interleukin 1 inhibitor, J. Immunol., 134(6): 3882-3886, Jun. 1985.*
Rosenstreich et al., A human urine-derived interleukin 1 inhibitor, J. Exp. Med., 168: 1767-1779, Nov. 1988.*
Arend et al., “Effects of Immune Complexes on Production by Human Monocytes of Interleukin 1 or Interleukin 1 Inhibitor”, J. Immunol., 134(6):3868-3875 (1985).
Arend et al., “An IL-1 Inhibitor from Human Monocytes”, J. Immunol., 143(6):1851-1858 (1989).
Arend et al., “Biological Properties of Recombinant Human Monocyte-derived Interleukin 1 Receptor Antagonist”, J. Clin. Invest., 85:1694-1697 (May 1990).
Balavoine et al., “Identification of Interleukin 1-like Activity and Inhibitor(s) in Urine from a Patient with Acute Monoblastic Leukemia”, Lymphokine Res., 3(4):233A (Abstract) (1984).
Balavoine et al., “Prostaglandin E2 and Collagenase Production by Fibroblasts and Synovial Cells is Regulated by Urine-derived Human Interleukin 1 and Inhibitor(s)”, J. Clin. Invest., 78:1120-1124 (1986).
Barak et al., “Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20)”, Eur. J. Immunol., 16:1449-1452 (1986).
Barak et al., “Interleukin 1 Inhibitor: Characterization of Mechanism of Activity”, Lymphokine Res. 7:268 (Abstract No. 1.32) (1988).
Beck et al., “Production of Interleukin 1 and A C1q Induced Interleukin 1 Inhibitor by B-CLL Cells”, RES 1987 Annual Meeting (Abstract No. 232).
Bienkowski et al., “Purification and Characterization of Interleukin 1 Receptor Level Antagonist Proteins from THP-1 Cells”, J. Biol. Chem., 265(24):14505-14511 (1990).
Billingham et al., “Interleukin-1: Its Relevance to Rheumatoid Arthritis”, British J. Rheum., 24 (suppl. 1):25-28 (1985).
Biotechnology Bulletin (1994) Jul. 31, 1994, 13(6):2 (100-199 words).
Bories et al., “Human α 1-Acid Glycoprotein-exposed Macrophages Release Interleukin 1 Inhibitory Activity”, Biochem. and Biophys. Res. Comm., 147(2):710-715 (1987).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science, 247:1306-1310 (1990).
Brown et al., “Mechanism of Action of a Human Interleukin-1 Inhibitor”, J. Leukocyte Biol., 37:688-689 (Abstract) (1985).
Bulletin International d'Informations (Droit et Pharmacie), Sep. 21, 1994, 8/9 p. 89(100-199 words).
Cannon et al., “Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever”, Journal of Infectious Diseases, 161:79-84 (1990).
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein”, Nature, 344:633-638 (1990).
Catalano, “Clinical Use of Human Recombinant IL-1 Receptor Antagonist”, Keystone Symposium on Cytokines and Cytokine Receptors, Jan. 31-Feb. 7, 1993, p. 55 (Abstract No. E016).
Cominelli et al., “Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease”, Biotherapy, 1(4):369-375 (1989).
Cominelli et al., “Regulation of Eicosanoid Production in Rabbit Colon by Interleukin-1”, Gastroenterology, 97(6):1400-1405 (1989).
Cominelli et al., “Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis”, J. Clin. Invest., 86:972-980 (1990).
Conti et al.,“Human Recombinant Interleukin-1 Receptor Antagonist (hrIL-1ra) Enhances the Stimulatory Effect of Interleukin-2 on Natural Killer Cell Activity Against Molt-4 Target Cells”, Int. J. Immunopharmac, 14(6):987-993 (1992).
Dinarello, “Interleukin-1 and Interleukin-1 Antagonism”, Blood, 77(8):1627-1652 (1991).
Dinarello et al., “Interleukin-1”, Digestive Dieseases & Sciences, 33(3):25S-35S (1988).
Dinarello et al., “Interleukins”, Ann. Rev. Med., 37:173-178 (1986).
Durum et al., “Interleukin 1: An Immunological Perspective”, Ann. Rev. Immunol., 3:263-287 (1985).
Eichacker et al., “The Effects of Human Recombinant Interleukin-1 (IL-1) on Canine Alveolar Neutrophil(N) Number and Lung Function”, Critical Care Medicine, Apr. 1989, p. S58 (Abstract).
Ferrara, “The Role of Interleukin 1 (IL-1) and IL-1 Receptor Antagonist in Graft-Versus-Host Disease”, Keystone Symposium on Cellular Immunity & the Immuno-therapy of Cancer, Mar. 17-24, 1993, p. 96 (Abstract No. NZ 019).
Furutani et al., “Cloning and characterization of the cDNAs for human and rabbit interleukin-1 precursor”, Nucleic Acids Res., 13(16):5869-5882 (1985).
Girardin et al., “Tumor Necrosis Factor and Interleukin-1 in the Serum of Children with Severe Infectious Purpura”, New England Journal of Medicine, 319(7):397-400 (1988).
Hall, “Isolation and partial purification of an inhiitor to interleukin 1”, Chem. Abstr., 105(17):539, abstract No. 151238W (Diss. Abstr. Int. B, 46(12), pt. 1, 4191 (1986).
Hall, “Isolation and Partial Purification of an Inhibitor to Interleukin I,” a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University, VCU, Richmond, VA, pp. 1-218 (Dec. 1985).
Helfman et al., “Identification of clones that encode chicken tropomyosin by direct immunological screening of a cDNA expression library”, Proc. Natl. Acad. Sci. USA, 80:31-35 (1983).
Hill et al., “Interleukin 1: A Regulatory Role in G
Arend William P.
Eisenberg Stephen P.
Hannum Charles H.
Joslin Fenneke G.
Sommer Andreas
Amgen Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Spector Lorraine
The Regents of the University of Colorado
LandOfFree
Nucleic acids encoding interleukin-1 inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding interleukin-1 inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding interleukin-1 inhibitors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448453